X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8992) 8992
Newsletter (71) 71
Magazine Article (26) 26
Book / eBook (24) 24
Newspaper Article (10) 10
Publication (7) 7
Book Chapter (3) 3
Conference Proceeding (3) 3
Dissertation (2) 2
Transcript (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8036) 8036
female (5008) 5008
oncology (4076) 4076
antineoplastic agents, hormonal - pharmacology (2877) 2877
breast neoplasms - drug therapy (2841) 2841
animals (2737) 2737
male (2508) 2508
breast cancer (2335) 2335
cancer (2285) 2285
pharmacology & pharmacy (2200) 2200
middle aged (2068) 2068
antineoplastic agents, hormonal - therapeutic use (1944) 1944
antineoplastic agents - pharmacology (1889) 1889
aged (1788) 1788
cell line, tumor (1556) 1556
breast neoplasms - pathology (1537) 1537
antineoplastic agents - therapeutic use (1527) 1527
chemotherapy (1526) 1526
adult (1467) 1467
tamoxifen (1464) 1464
tamoxifen - pharmacology (1339) 1339
treatment outcome (1162) 1162
mice (1146) 1146
breast neoplasms - metabolism (1136) 1136
expression (1135) 1135
medicine & public health (1114) 1114
care and treatment (1092) 1092
apoptosis (1089) 1089
research (1011) 1011
prostatic neoplasms - drug therapy (958) 958
therapy (883) 883
antineoplastic combined chemotherapy protocols - therapeutic use (875) 875
cell proliferation - drug effects (870) 870
prostate cancer (859) 859
apoptosis - drug effects (833) 833
tamoxifen - therapeutic use (832) 832
drug resistance, neoplasm (831) 831
dose-response relationship, drug (790) 790
tumors (773) 773
health aspects (764) 764
drug therapy (748) 748
antineoplastic agents (732) 732
estrogen (728) 728
breast neoplasms - genetics (720) 720
neoplasms - drug therapy (719) 719
analysis (705) 705
pharmacology/toxicology (701) 701
aged, 80 and over (672) 672
antineoplastic agents, hormonal - administration & dosage (667) 667
postmenopausal women (667) 667
tumor cells, cultured (665) 665
metastasis (656) 656
biochemistry & molecular biology (619) 619
growth (615) 615
antineoplastic agents - adverse effects (610) 610
breast-cancer (607) 607
antimitotic agents (602) 602
rats (582) 582
prostatic neoplasms - pathology (566) 566
cell biology (544) 544
antineoplastic agents, hormonal - adverse effects (539) 539
antineoplastic agents - administration & dosage (535) 535
cells (533) 533
carcinoma (532) 532
signal transduction - drug effects (524) 524
receptors, estrogen - metabolism (523) 523
endocrinology & metabolism (518) 518
in-vitro (514) 514
prognosis (512) 512
cancer therapies (493) 493
cancer research (479) 479
gene expression (478) 478
time factors (472) 472
clinical trials as topic (470) 470
signal transduction (469) 469
neoplasm metastasis (463) 463
chemotherapy, adjuvant (440) 440
disease-free survival (439) 439
pharmacology (436) 436
estradiol - pharmacology (435) 435
gene expression regulation, neoplastic - drug effects (425) 425
clinical trials (420) 420
proteins (420) 420
survival (420) 420
activation (418) 418
estrogen-receptor (415) 415
gene expression regulation, neoplastic (409) 409
women (408) 408
mice, nude (405) 405
endocrine therapy (404) 404
aromatase inhibitors (402) 402
inhibition (398) 398
mcf-7 cells (398) 398
internal medicine (388) 388
medicine (384) 384
cell survival - drug effects (375) 375
gene-expression (368) 368
docetaxel (366) 366
resistance (360) 360
antineoplastic combined chemotherapy protocols - adverse effects (358) 358
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8985) 8985
Chinese (45) 45
French (34) 34
Japanese (33) 33
German (29) 29
Russian (28) 28
Italian (15) 15
Spanish (14) 14
Hungarian (4) 4
Czech (2) 2
Korean (2) 2
Polish (2) 2
Ukrainian (2) 2
Danish (1) 1
Finnish (1) 1
Hebrew (1) 1
Norwegian (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular cancer, ISSN 1476-4598, 2013, Volume 12, Issue 1, pp. 9 - 9
Background: Estrogen receptor-alpha (ER alpha)-negative breast cancer is clinically aggressive and normally does not respond to conventional estrogen... 
Breast cancer | Epigenetic | Tamoxifen | ERα | Genistein | CELLS | HISTONE DEACETYLASE INHIBITOR | METHYLATION | ACTIVATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | TRICHOSTATIN-A | IN-VITRO | ONCOLOGY | GROWTH | GENES | EXPRESSION | ER alpha | Gene Expression - drug effects | Humans | Tamoxifen - administration & dosage | DNA (Cytosine-5-)-Methyltransferases - metabolism | Anticarcinogenic Agents - administration & dosage | Estrogen Receptor alpha - metabolism | Female | Genistein - administration & dosage | Epigenesis, Genetic - drug effects | Anticarcinogenic Agents - pharmacology | Hydroxamic Acids - pharmacology | Estradiol - pharmacology | Cell Survival - drug effects | Promoter Regions, Genetic | Antineoplastic Agents, Hormonal - pharmacology | DNA (Cytosine-5-)-Methyltransferase 1 | Antineoplastic Agents, Hormonal - administration & dosage | Azacitidine - analogs & derivatives | Mice, Transgenic | Breast Neoplasms - drug therapy | Breast Neoplasms - prevention & control | Drug Synergism | Xenograft Model Antitumor Assays | Azacitidine - pharmacology | Animals | Estrogen Receptor alpha - genetics | Tumor Burden - drug effects | Breast Neoplasms - pathology | Mice, Nude | Genistein - pharmacology | Tamoxifen - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Mice | Histones - metabolism | Proliferating Cell Nuclear Antigen - metabolism | Drug Resistance, Neoplasm - drug effects | Histone Deacetylase 1 - metabolism
Journal Article
Cancer Research, ISSN 0008-5472, 12/2011, Volume 71, Issue 24, pp. 7597 - 7607
Insulin-like growth factor (IGF) signaling has been implicated in the resistance to hormonal therapy in breast cancer... 
INSULIN-RECEPTOR ISOFORM | TAMOXIFEN WITHDRAWAL | ACTIVATION | THERAPY | EXEMESTANE | ONCOLOGY | TRANSCRIPTION | RESISTANCE | POSTMENOPAUSAL WOMEN | EXPRESSION | GROWTH-FACTOR-I | Receptor, IGF Type 1 - metabolism | Triazoles - administration & dosage | Estradiol - analogs & derivatives | Receptor, IGF Type 1 - antagonists & inhibitors | Nitriles - pharmacology | Oligonucleotide Array Sequence Analysis | Humans | Gene Expression Profiling | Mammary Neoplasms, Experimental - metabolism | Tamoxifen - administration & dosage | Mammary Neoplasms, Experimental - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Receptor, Insulin - genetics | Female | Estrogens - metabolism | Estradiol - pharmacology | Mammary Neoplasms, Experimental - drug therapy | Pyrazoles - pharmacology | Triazines - pharmacology | Antineoplastic Agents, Hormonal - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Estradiol - administration & dosage | Receptor, Insulin - antagonists & inhibitors | Receptor, IGF Type 1 - genetics | Blotting, Western | Drug Synergism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | Tamoxifen - pharmacology | Cell Line, Tumor | Tamoxifen - analogs & derivatives | Receptor, Insulin - metabolism | Cell Proliferation - drug effects | Mice | Mice, Inbred BALB C
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2013, Volume 49, Issue 18, pp. 3821 - 3830
Journal Article
Molecular cancer therapeutics, ISSN 1538-8514, 2012, Volume 11, Issue 11, pp. 2352 - 2361
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2010, Volume 130, Issue 2, pp. 377 - 385
The estrogen receptor (ER) is implicated in the progression of breast cancer. Despite positive effects of hormonal therapy, initial or acquired resistance to endocrine therapies frequently occurs... 
Estrogen receptor | Therapy resistance | Medicine & Public Health | Src | Oncology | Breast cancer | HER2 | Extranuclear signaling | PELP1 | COREGULATOR | TAMOXIFEN | MECHANISMS | ESTROGEN-RECEPTOR | BREAST-CANCER CELLS | PROLINE-RICH | ONCOLOGY | RECEPTOR COACTIVATOR PELP1/MNAR | NONGENOMIC ACTIONS | AROMATASE INHIBITORS | GLUTAMIC-ACID-RICH | Phosphorylation | Nitriles - pharmacology | Humans | Receptor, ErbB-2 - metabolism | Co-Repressor Proteins - metabolism | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Thiazoles - therapeutic use | Gene Knockdown Techniques | RNA Interference | src-Family Kinases - metabolism | Estrogen Receptor alpha - metabolism | Female | Antineoplastic Agents - pharmacology | Triazoles - therapeutic use | Dasatinib | Pyrimidines - pharmacology | Transcription Factors - genetics | Breast Neoplasms - drug therapy | Co-Repressor Proteins - genetics | Drug Synergism | Transcription Factors - metabolism | Triazoles - pharmacology | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Breast Neoplasms - pathology | Mice, Nude | Pyrimidines - therapeutic use | Tamoxifen - therapeutic use | Tamoxifen - pharmacology | Cell Line, Tumor | Mice | Thiazoles - pharmacology | src-Family Kinases - genetics | Mitogen-Activated Protein Kinases - metabolism | Nitriles - therapeutic use | Analysis | Estrogen | Development and progression | Postmenopausal women | Tamoxifen | Health aspects | Tumors
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 23, pp. 3742 - 3748
Journal Article
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 1945-7197, 2013, Volume 98, Issue 12, pp. 4551 - 4564
.... Thus, major players in the pathogenesis are still unknown. For diagnostic workup, comprehensive hormonal assessment and detailed imaging are required... 
GROWTH-FACTOR RECEPTOR | POSITRON-EMISSION-TOMOGRAPHY | LAPAROSCOPIC ADRENALECTOMY | CANCER-PATIENTS | STEROIDOGENIC FACTOR-1 | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | PHASE-II | ADJUVANT RADIOTHERAPY | BETA-CATENIN | PROGNOSTIC VALUE | Adrenal Glands - pathology | Lymph Node Excision | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Adrenocortical Carcinoma - surgery | Humans | Adrenocortical Carcinoma - diagnosis | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Neoplasm Proteins - metabolism | Mitotane - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Adrenal Cortex Neoplasms - diagnosis | Adrenocortical Carcinoma - drug therapy | Antineoplastic Agents, Hormonal - therapeutic use | Adrenocortical Carcinoma - metabolism | Chemotherapy, Adjuvant | Adrenal Glands - drug effects | Mitotane - administration & dosage | Adrenal Cortex Neoplasms - metabolism | Antineoplastic Agents, Hormonal - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Adrenal Cortex Neoplasms - surgery | Adrenal Glands - surgery | Mitotane - therapeutic use | Adrenal Cortex Neoplasms - drug therapy | Animals | Adrenal Glands - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Decision Trees | Neoplasm Staging
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 22, pp. 1665 - 1675
Recent advances in tumor biology have made remarkable achievements in the development of therapy for metastatic castrate-resistant prostate cancer. These... 
GROWTH-FACTOR RECEPTOR | CONTROLLED-TRIAL | ANTIANGIOGENIC THERAPY | ONCOLOGY | RANDOMIZED PHASE-II | BONE METASTASES | C-MET | SIPULEUCEL-T APC8015 | ABIRATERONE ACETATE | TUMOR MICROENVIRONMENT | ANGIOGENESIS INHIBITION | Cancer Vaccines - pharmacology | Humans | Male | Antineoplastic Agents - therapeutic use | Bevacizumab | Prostatic Neoplasms - immunology | RANK Ligand - pharmacology | Receptors, Androgen - drug effects | Treatment Failure | Prostatic Neoplasms - drug therapy | Phenylthiohydantoin - pharmacology | Tumor Microenvironment - drug effects | Dasatinib | Antibodies, Monoclonal - pharmacology | Angiogenesis Inhibitors - pharmacology | Clusterin - pharmacology | Pyrimidines - pharmacology | Denosumab | Prostate-Specific Antigen - blood | Orchiectomy | Signal Transduction - drug effects | Anilides - pharmacology | Mice | Receptor Cross-Talk - drug effects | Endothelin-1 - antagonists & inhibitors | Immunotherapy - methods | Taxoids - pharmacology | Ipilimumab | Tissue Extracts - pharmacology | Bone Remodeling - drug effects | Pyrrolidines - pharmacology | Antibodies, Monoclonal, Humanized - pharmacology | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Prostatic Neoplasms - pathology | Antineoplastic Agents, Hormonal - pharmacology | Androstenols - pharmacology | Androstenes | Clinical Trials as Topic | Mice, SCID | Phenylthiohydantoin - analogs & derivatives | Biomarkers, Tumor - blood | Xenograft Model Antitumor Assays | Cancer Vaccines - immunology | Pyrroles - pharmacology | Animals | RANK Ligand - antagonists & inhibitors | Pyridines - pharmacology | Thiazoles - pharmacology | Immune response | Development and progression | Cellular signal transduction | Research | Drug therapy | Health aspects | Prostate cancer | Risk factors | Review
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 1945-7197, 2012, Volume 97, Issue 2, pp. 507 - 516
... and after addition of dexamethasone 0.5 mg daily. Results: Treatment with single-agent abiraterone acetate was associated with accumulation of steroids with mineralocorticoid properties upstream of CYP17A1... 
TRIAL | HUMAN CYTOCHROME P450(17-ALPHA) | CELLS | PATHWAY | STEROIDAL INHIBITORS | GUIDELINES | ENDOCRINOLOGY & METABOLISM | KETOCONAZOLE | ACETATE | DIHYDROTESTOSTERONE | REMAINS | Androstenols - adverse effects | Prostatic Neoplasms - metabolism | Steroid 17-alpha-Hydroxylase - antagonists & inhibitors | Glucocorticoids - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Enzyme Inhibitors - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Chemotherapy, Adjuvant | Glucocorticoids - adverse effects | Prostatic Neoplasms - drug therapy | Biomarkers - metabolism | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Biomarkers, Pharmacological - analysis | Antineoplastic Agents, Hormonal - pharmacology | Prostatic Neoplasms - surgery | Androstenols - pharmacology | Antineoplastic Agents, Hormonal - administration & dosage | Carcinoma - surgery | Biomarkers - analysis | Enzyme Inhibitors - pharmacology | Androstenes | Treatment Outcome | Disease Progression | Orchiectomy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Androstenols - administration & dosage | Steroid 17-alpha-Hydroxylase - metabolism | Carcinoma - metabolism | Biomarkers, Pharmacological - metabolism
Journal Article
Journal Article